Developing Novel Therapies from Neonatal Cardiac Progenitor Cells (nCPCs)
At Secretome Therapeutics, we harness the unique biology of neonatal cardiac progenitor cells to develop transformative therapies targeting severe cardiovascular and inflammatory diseases.
Advancing Science, Transforming Lives
At Secretome Therapeutics, we aim to redefine treatment for life-threatening diseases by leveraging the power of neonatal cardiac progenitor cells (nCPCs). Our mission is to improve lives through innovative science, scalable solutions, and targeted therapies.
Our Science
Our platform utilizes neonatal cardiac progenitor cells to produce therapies that reduce inflammation, prevent fibrosis, and support tissue repair.
Our Pipeline
Our lead candidate, STM-01, is in Phase 1 clinical trials, with additional pipeline programs addressing critical unmet needs.
Clinical Progress
With secured patents and ongoing trials, we are advancing first-in-class therapies to address complex diseases and improve patient outcomes.
Please contact us directly with any questions,
comments, or inquiries you may have.
Secretome Therapeutics
323 W. Camden Street, Suite 600
Baltimore, MD 21201
400 N. Aberdeen Street, Suite 900
Chicago, IL 60642
7250 Dallas Parkway, Suite 400
Plano, TX 75024
3060 Pegasus Park Drive, Building 6
Dallas, TX 75247